一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Stereotactic Radiation Therapy；Envafolimab；Endostar，当前状态为尚未开始招募。登记地点显示中国连云港有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Stereotactic Radiation Therapy；Envafolimab；Endostar · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Lianyungang First People's Hospital · 连云港
公开的入选条件
- 1. Subjects voluntarily participate in this study, sign the written informed consent form, and demonstrate good compliance.
- 2. Aged 18-80 years old at the time of signing informed consent, male or female.
- 3. Histologically confirmed stage IV non-small-cell lung cancer (NSCLC) according to the 8th IASLC/AJCC TNM staging system, with negative actionable driver gene alterations (EGFR/ALK/ROS1), and no prior systemic anti-cancer treatment.
- 4. Provide archived tumor tissue samples or newly obtained core/excisional biopsy specimens from tumor lesions which have not received prior anti-tumor therapy or radiotherapy. Formalin-fixed paraffin-embedded (FFPE) tissue blocks are preferred over slides; ne
- 5. Have at least one radiologically measurable lesion per RECIST version 1.1: target lesion with longest diameter ≥10 mm on CT/MRI, or pathologically enlarged lymph node with short-axis diameter ≥15 mm on CT scan.
- 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- 7. Expected survival time ≥ 3 months.
- 8. Treatment-naive patients without previous systemic anti-tumor therapy (including radiotherapy, chemotherapy, targeted or immunotherapy), or patients with disease recurrence more than 6 months after completion of postoperative adjuvant chemotherapy.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07818304；登记信息更新于 2026-09-14。